Approval isn't access: judge launches by payer and formulary milestones, not shipments

Three launches, one lesson

Read this week's company updates side by side and a pattern emerges that no single press release states. Regulatory clearance and commercial availability are the easy milestones. Access is slower, institution by institution and payer by payer, and it is the part that decides whether a launch works.

Replimune says its oncolytic HSV-1 therapy Tudriqev, given with nivolumab for advanced melanoma, became commercially available in early October after accelerated approval. The company's own wording is telling: NCCN listing and payer policies are 'emerging' while the confirmatory Phase 3 trial enrols. That is a product on the market with its coverage position still forming, and the evidence that will shape that position not yet in.

Amarin's update points the same way. The company posted a slim third-quarter 2026 net profit despite a 20% revenue fall, while partner Recordati began non-reimbursed sales of icosapent ethyl in Poland. Selling a product that is privately paid is a legitimate way to enter a market. It is not reimbursed access, and the records give no reason to treat the two as equivalent.

Uptake numbers need careful reading

Citius Oncology offers the most concrete data. Its preliminary, unaudited figures show wholesalers bought 792 units of LYMPHIR in the quarter ended 30 September, up from 360 the quarter before, a 120% rise. Institutions that have ordered the product rose to 54 from 44. The company is aiming for formulary placement at 100 priority institutions by calendar year-end and plans full results in December.

That is encouraging. But look at what is counted: wholesaler purchases and ordering institutions. Neither is the same as formulary placement, and neither shows patients treated. The company's own target, 100 priority institutions with formulary placement, shows that it sees the formulary as the real gate. The product was launched in December 2025, so these figures describe a launch that is still being built ten months on.

The rules of access are moving too

Elsewhere in the records, the machinery that governs access keeps changing at the edges. AIFA updated the monitoring registry for FABHALTA (iptacopan) in C3 glomerulopathy. Registries like this are how prescribing and reimbursement are managed in Italy, so a revision matters even though the notice does not say what changed. In the EU, the Commission updated its procedural guidance for HTA joint scientific consultations to add the role of a 'watcher'. The source does not say who the watcher is or what the role involves. The HTACG also published a flash report of its 22 October meeting, with no topics or decisions given in the input.

We should not over-read these items, and we won't speculate. The point is simpler: the access environment is procedural, and procedure changes. Teams that learn about it from the full documents rather than headlines will be ahead.

The strongest counter-argument

The best objection is that early uptake is a legitimate leading indicator, and that private-pay or institution-by-institution entry is how many launches begin. Citius's numbers do show momentum, and Recordati's Polish sales do put product in the market. Waiting for full reimbursement before calling a launch a success would be unrealistic.

That is fair. But it argues for better measurement, not for treating shipments as access. A launch with rising wholesaler units and a stalled formulary count is a different business from one where both advance. Only teams that track the two separately will know which they have.

Our position

Market access should own a defined set of access milestones for every launch, separate from the commercial and regulatory ones. Where approval is conditional, as with Tudriqev, the confirmatory evidence plan is part of the access plan, because payer policies are being written while that evidence is still being generated.